These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

472 related items for PubMed ID: 18854676

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project.
    Bandak G, Sang Y, Gasparini A, Chang AR, Ballew SH, Evans M, Arnlov J, Lund LH, Inker LA, Coresh J, Carrero JJ, Grams ME.
    J Am Heart Assoc; 2017 Jul 19; 6(7):. PubMed ID: 28724651
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Raebel MA.
    Cardiovasc Ther; 2012 Jun 19; 30(3):e156-66. PubMed ID: 21883995
    [Abstract] [Full Text] [Related]

  • 5. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine?
    Ahmed A.
    J Am Geriatr Soc; 2002 Jul 19; 50(7):1297-300. PubMed ID: 12133029
    [Abstract] [Full Text] [Related]

  • 6. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
    Khosla N, Kalaitzidis R, Bakris GL.
    Am J Nephrol; 2009 Jul 19; 30(5):418-24. PubMed ID: 19738369
    [Abstract] [Full Text] [Related]

  • 7. Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments.
    Hirai T, Yamaga R, Fujita A, Itoh T.
    J Clin Pharm Ther; 2018 Dec 19; 43(6):829-835. PubMed ID: 29908131
    [Abstract] [Full Text] [Related]

  • 8. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
    Han SW, Won YW, Yi JH, Kim HJ.
    Nephrol Dial Transplant; 2007 Apr 19; 22(4):1150-5. PubMed ID: 17255126
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease.
    Fröhlich H, Nelges C, Täger T, Schwenger V, Cebola R, Schnorbach J, Goode KM, Kazmi S, Katus HA, Cleland JG, Clark AL, Frankenstein L.
    Am Heart J; 2016 Aug 19; 178():28-36. PubMed ID: 27502849
    [Abstract] [Full Text] [Related]

  • 12. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
    Heerspink HJ, Gao P, de Zeeuw D, Clase C, Dagenais GR, Sleight P, Lonn E, Teo KT, Yusuf S, Mann JF.
    Eur J Prev Cardiol; 2014 Mar 19; 21(3):299-309. PubMed ID: 24191305
    [Abstract] [Full Text] [Related]

  • 13. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
    Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA, AMETHYST-DN Investigators.
    JAMA; 2015 Jul 14; 314(2):151-61. PubMed ID: 26172895
    [Abstract] [Full Text] [Related]

  • 14. [Risk for hyperkalemia during long-term treatment with angiotensin-converting enzyme inhibitors in insulin-dependent type 2 diabetics in relation to the glomerular filtration rate].
    Raml A, Schmekal B, Grafinger P, Biesenbach G.
    Dtsch Med Wochenschr; 2001 Nov 23; 126(47):1327-30. PubMed ID: 11719857
    [Abstract] [Full Text] [Related]

  • 15. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR, Rolfe M.
    Clin J Am Soc Nephrol; 2010 Mar 23; 5(3):531-48. PubMed ID: 20150448
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic.
    Sarafidis PA, Blacklock R, Wood E, Rumjon A, Simmonds S, Fletcher-Rogers J, Ariyanayagam R, Al-Yassin A, Sharpe C, Vinen K.
    Clin J Am Soc Nephrol; 2012 Aug 23; 7(8):1234-41. PubMed ID: 22595825
    [Abstract] [Full Text] [Related]

  • 20. Prescriptions for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and monitoring of serum creatinine and potassium in patients with chronic kidney disease.
    Wang PT, Huang YB, Lin MY, Chuang PF, Hwang SJ.
    Kaohsiung J Med Sci; 2012 Sep 23; 28(9):477-83. PubMed ID: 22974666
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.